ACTAVIS LABS
DEAD

Serial Number

79129809

Owner

Actavis Group PTC ehf

Attorney

GABRIELLE S. ROTH

Filing Date

Nov 21, 2012

Add to watchlist:

No watchlists yet
View on USPTO

ACTAVIS LABS Trademark

Serial Number: 79129809

ACTAVIS LABS is a trademark filed by Actavis Group PTC ehf on November 21, 2012. The trademark is classified under Class 1 (Chemicals), Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Actavis Group PTC ehf (50 trademarks)

Dalshraun 1

Entity Type: 78

Trademark Details

Filing Date

November 21, 2012

Registration Date

Not Registered

Goods & Services

Educational services, namely, conducting conferences, seminars, webinars, video case studies, classes and workshops in the fields of healthcare, women's health, pharmaceuticals and medicine, pharmaceutical research and development

Pharmaceutical preparations for the prevention and treatment of alimentary tract and metabolic diseases and disorders, dermatological diseases and disorders, genito-urinary and sexual diseases and disorders, musculo-skeletal system diseases and disorders, nervous system diseases and disorders, respiratory system diseases and disorders, cardio-vascular diseases and disorders specifically excluding tissue plasminogen activators; pharmaceutical preparations for the prevention and treatment of sensory organ diseases and disorders, systemic hormonal pharmaceutical preparations and substances, pharmaceuticals, namely, anti-infectives, pharmaceutical preparations, namely, antineoplastic and immunomodulating agents, antiparasitic preparations and substances; contraceptives; hormone replacement therapy preparations; pharmaceutical preparations for the prevention of preterm birth or pregnancy; pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; pharmaceutical preparations for the treatment and prevention of osteoporosis; pharmaceutical preparations for the treatment and prevention of endometriosis; pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; iron chelating pharmaceutical preparations; fertility enhancing preparations, pharmaceutical preparations and substances for the treatment of premenstrual syndrome, post natal depression, fluctuating hormone levels, pharmaceutical preparations and substances for infertility disorders, pharmaceutical preparations and substances for in vitro fertilization (ivf); pharmaceutical preparations in the nature of medicated dental rinses, mouth rinses, mouthwashes, dental lozenges, dental tablets and medicated chewing gum; dental wax; pharmaceutical preparations in the nature of pregnancy test kits, ovulation test kits and in-vitro ovulation prediction test kits all for home use. pharmaceutical preparations in the nature of diagnostic test kits for home use for detecting urinary tract infections, for detecting menopause, for detecting vaginal pH balances and for detecting sexually-transmitted diseases; pharmaceutical preparations for skin care

Soaps; Perfumery; Essential Oils; Cosmetics, namely, cosmetic preparations for skin care, cosmetic preparations for body care, cosmetic preparations for bath and shower, cosmetic creams, lotions, and ointments and gels for skin care, cosmetic skin fresheners and toners, cosmetic preparations for the hair and scalp, and hair lotions; Dentifrices, namely, anti-cavity dental rinses, mouth rinses and mouth washes, cosmetic preparations for the care of mouth and teeth

Chemicals used in industry and science, namely, active chemical ingredients for use in the manufacture of pharmaceuticals, chemical additives for use in the manufacture of pharmaceuticals; chemical preparations for scientific purposes; chemical preparations for use in industry

Scientific and technological services, namely, consulting in the field of pharmaceuticals pertaining to biotechnology, product evaluation, diagnostics, testing and inspection; pharmaceutical research and development; industrial analysis and research services in the field of pharmaceuticals and chemical analysis

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Jun 18, 2023 DENA
DEATH OF INTERNATIONAL REGISTRATION
Jun 17, 2023 DETH
NEW REPRESENTATIVE AT IB RECEIVED
Oct 22, 2022 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 3, 2015 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Mar 19, 2015 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 19, 2015 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Dec 26, 2014 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 10, 2014 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 10, 2014 OPNR
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Mar 19, 2014 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Mar 19, 2014 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 21, 2013 GNFN
FINAL REFUSAL E-MAILED
Aug 21, 2013 GNFR
FINAL REFUSAL WRITTEN
Aug 21, 2013 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 30, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 30, 2013 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 24, 2013 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 16, 2013 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 16, 2013 REAP
DATA MODIFICATION COMPLETED
Jul 9, 2013 DMCC
ASSIGNED TO LIE
Jul 9, 2013 ALIE
ATTORNEY REVIEW COMPLETED
Jul 9, 2013 ATRV
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
Jul 8, 2013 CREV
REFUSAL PROCESSED BY IB
Jul 7, 2013 RFNT
CORRECTION TRANSACTION RECEIVED FROM IB
Jul 6, 2013 CRCV
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 7, 2013 RFCS
REFUSAL PROCESSED BY MPU
Jun 7, 2013 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 7, 2013 RFCR
NON-FINAL ACTION WRITTEN
Jun 6, 2013 CNRT
NON-FINAL ACTION MAILED
Jun 4, 2013 CNRT
APPLICATION FILING RECEIPT MAILED
Jun 4, 2013 MAFR
NON-FINAL ACTION WRITTEN
Jun 3, 2013 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Jun 3, 2013 RFWR
NON-FINAL ACTION MAILED
Jun 3, 2013 CNRT
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 1, 2013 RFCR
NON-FINAL ACTION WRITTEN
May 31, 2013 CNRT
NON-FINAL ACTION WRITTEN
May 31, 2013 CNRT
ASSIGNED TO EXAMINER
May 29, 2013 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 29, 2013 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 23, 2013 REPR